Eli Lilly and Company (LLY)vsSol Gel Technologies Ltd (SLGL)
LLY
Eli Lilly and Company
$1,131.42
-2.41%
HEALTHCARE · Cap: $948.95B
SLGL
Sol Gel Technologies Ltd
$77.98
+4.85%
HEALTHCARE · Cap: $244.37M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 391175% more annual revenue ($72.25B vs $18.46M). LLY leads profitability with a 35.0% profit margin vs -5.7%. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
SLGL
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+48.1%
Fair Value
$127.32
Current Price
$77.98
$49.34 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Earnings expanding 487.6% YoY
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 32.4x book value
Smaller company, higher risk/reward
ROE of -2.0% — below average capital efficiency
Revenue declined 89.5%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : SLGL
The strongest argument for SLGL centers on EPS Growth, Debt/Equity.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book.
Bear Case : SLGL
The primary concerns for SLGL are Market Cap, Return on Equity, Revenue Growth.
Key Dynamics to Monitor
LLY profiles as a growth stock while SLGL is a turnaround play — different risk/reward profiles.
SLGL carries more volatility with a beta of 1.13 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (78/100 vs 24/100), backed by strong 35.0% margins and 55.5% revenue growth. SLGL offers better value entry with a 48.1% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Sol Gel Technologies Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Sol-Gel Technologies Ltd., a specialty clinical-stage pharmaceutical company, is focused on developing and commercializing topical dermatological pharmaceuticals based on its Israel-patented microencapsulation delivery system. The company is headquartered in Ness Ziona, Israel.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?